GleamWall
中文EN

PEPG PepGen Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835597 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY21.6%
TTM EPS YoY72.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.1%
ROA-46.1%
ROIC (approx.)-121.4%
Asset turnover—

Leverage & solvency

Liabilities / assets19.3%
Debt / equity0.00x
Current ratio8.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$14.48M$12.52M$13.00M$13.85M$13.42M$18.39M$25.38M$18.96M
SG&A expense$5.91M$6.42M$5.94M$5.85M$5.23M$5.54M$5.94M$5.38M
Operating income-$20.38M-$18.94M-$18.94M-$19.70M-$18.65M-$23.93M-$31.32M-$24.34M
Pretax income-$19.38M-$17.80M-$17.75M-$18.29M-$18.03M-$23.09M-$30.20M-$22.86M
Income tax$13,000$16,000$15,000$48,865$0$0$0-$617,000
Net income-$19.39M-$17.81M-$17.76M-$18.34M-$18.03M-$23.09M-$30.20M-$22.24M
EBITDA-$20.18M-$18.64M-$18.64M-$19.41M-$18.35M-$23.63M-$30.92M-$23.95M
EPS (basic)-0.28-0.26-0.26—-0.52-0.70-0.92—
EPS (diluted)-0.28-0.26-0.26—-0.52-0.70-0.92—
Weighted avg. shares (diluted)69.26M69.20M69.09M—34.36M32.75M32.67M—
Balance sheet
Cash & equivalents$21.96M$22.76M$42.15M$60.51M$142.78M$35.07M$43.63M$49.42M
Short-term investments$82.85M$94.47M$90.15M$87.94M$20.89M$39.58M$54.15M$70.77M
Current assets$107.57M$120.33M$134.27M$150.96M$166.21M$77.49M$101.05M$123.76M
PP&E, net$1.10M$1.34M$1.56M$1.90M$2.22M$2.49M$3.51M$3.72M
Total assets$127.78M$141.40M$156.29M$173.91M$190.06M$102.24M$127.39M$150.88M
Current liabilities$12.36M$9.01M$8.96M$12.65M$12.64M$16.36M$20.43M$16.70M
Total liabilities$24.71M$21.86M$22.32M$26.46M$26.92M$31.08M$35.59M$32.26M
Shareholders' equity$103.07M$119.53M$133.98M$147.44M$163.14M$71.16M$91.81M$118.62M
Shares outstanding———68.87M———32.62M
Cash flow statement
Operating cash flow-$13.18M-$15.81M-$18.43M-$15.85M-$19.26M-$23.60M-$22.93M-$19.48M
Capital expenditure$0$30,000$0-$1,000$97,000$43,000$125,000$228,000
Free cash flow-$13.18M-$15.84M-$18.43M-$15.84M-$19.36M-$23.64M-$23.05M-$19.70M
Investing cash flow$12.46M-$3.52M-$1.46M-$66.24M$18.90M$14.96M$17.15M$26.50M
Financing cash flow-$86,000-$65,000$1.52M-$171,000$108.05M$98,000$0$128,000
Depreciation & amortization$200,000$300,000$300,000$300,000$300,000$300,000$400,000$400,000
Stock-based compensation$2.96M$3.31M$2.85M$2.44M$2.38M$2.36M$3.43M$3.35M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.